Manhattan Research Releases Report on the Future of Physician Customer Service Portals

Manhattan ResearchOver the past year, physician visitation to customer service portals decreased while interest in using them actually increased. To help biopharma companies bridge the gap between the current portal landscape and unmet physician demand, pharmaceutical and healthcare market research company Manhattan Research just released its latest physician module report, "The Case for Customer Care: Service Portals and a Successfully Integrated CRM System" as part of its ePharma Physicianâ v8.0 market research and strategic advisory service. The report discusses future implications for physician customer service portals and reveals market data and best practices for biopharma companies looking to reach target audiences through this channel.

"Physicians rely on a diverse channel mix to gather biopharma and healthcare information and fewer of them are willing to take face-to-face sales rep meetings - challenging companies to re-invent the traditional service model," said the author of the report, Meredith Abreu Ressi, VP of research for Manhattan Research. "Many have begun building full-service portals for physicians where they can access journal reprints, order samples, download patient education information, and even videoconference online with a rep."

"Physicians are not saying that they want to do away with the sales force entirely," continues Ressi. "Most physicians still want to be able to talk to a rep when they have a question, or when there's a new product launch - but if it's a routine question or transaction, they'd prefer to conduct those activities online, when it's convenient for them. This is really about providing physicians with a variety of channels to access information so they can choose the method that is most convenient and useful to them."

Report Outline
I. Physician Portals: Where Are We Now?

  • Trending and Current Adoption
  • Top Portals
  • Physician Demand for Portals (by company)
  • Who Uses Portals Today?

II. Developing a Physician Portal: Features and Physician Expectations

  • What Are They Using? What do They Want to Use?
  • Differences by Specialty
  • Features to Consider
    • Email Customer Service
    • Live Video Rep or Call Center
    • Integrating Medical Affairs

III. If You Build It, They Won’t Just Come: Marketing Your Portal

  • Marketing the Portal Online
  • Top Portals
  • Selling the Site: Public vs. Password-Protected Content
  • Sales Force Buy-in
  • Closed Loop CRM

More information about the report’s contents can be found here:
http://www.manhattanresearch.com/products/Research_Modules/
Physician/physician-customer-service-portals.aspx

About ePharma Physician® v8.0
ePharma Physician® v8.0 was conducted via online survey methodology in Q2 2008 among 1,681 online practicing U.S. physicians. The study and advisory service product has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit and provides in-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters, society sites, physicians and Web 2.0, physician online communities, electronic detailing, Tablet PCs, online conferences, physician customer service portals, tech-enabled sales forces, physician CRM, and more. For more information, visit: http://www.manhattanresearch.com/products/Strategic_Advisory/ePP/

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory firm for pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...